NCT01957735View on ClinicalTrials.gov

BP31510 (Ubidecarenone,USP) Nanosuspension for Intravenous Injection to Patients With Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

97

Participants

Timeline

Start Date

October 31, 2013

Primary Completion Date

February 1, 2017

Study Completion Date

February 1, 2017

Conditions
Metastatic CancerCancerSolid Tumor
Interventions
DRUG

BP31510 monotherapy

DRUG

BP31510 in combination with chemotherapy

Trial Locations (3)

10021

Weill Cornell Solid Tumor Oncology Practice, New York

77030

The University of Texas MD Anderson Cancer Center, Houston

94086

Palo Alto Medical Foundation, Sunnyvale

All Listed Sponsors
lead

BPGbio

INDUSTRY

NCT01957735 - BP31510 (Ubidecarenone,USP) Nanosuspension for Intravenous Injection to Patients With Solid Tumors | Biotech Hunter | Biotech Hunter